| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
26,184,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
831,818 |
Avg
Vol: |
829,539 |
| 52
Week Range: |
$0.000001 - $0.0001 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile EPIRUS Biopharmaceuticals is a global biopharmaceutical company focused on building a biosimilar business. Co.'s primary product candidate is BOW015 (infliximab), a monoclonal antibody against tumor necrosis factor alpha, which is used to treat inflammatory diseases. Co.'s other pipeline products, BOW050 (adalimumab), a proposed biosimilar to Humira, BOW070 (tocilizumab), a proposed biosimilar to Actemra, BOW080 (eculizumab), a proposed biosimilar to Soliris, BOW090 (ustekinumab), a proposed biosimilar to STELARA and BOW100 (golimumab), a proposed biosimilar to SIMPONI, are in preclinical development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Montreux Equity Partners V, L.p. |
10% Owner |
– – • |
2015-01-26 |
4 |
S |
$6.47 |
$249,102 |
D/D |
(38,516) |
1,891,400 |
|
- |
|
| Montreux Equity Partners V, L.p. |
10% Owner |
– – • |
2015-01-23 |
4 |
S |
$6.27 |
$52,699 |
D/D |
(8,400) |
1,929,916 |
|
- |
|
| Montreux Equity Partners V, L.p. |
10% Owner |
– – • |
2015-01-22 |
4 |
S |
$6.30 |
$88,979 |
D/D |
(14,130) |
1,938,316 |
|
- |
|
| Rocklage Scott M |
Director |
– • • |
2014-07-15 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
2,214,910 |
|
- |
|
| Livzon Mabpharm Inc. |
10% Owner |
– – • |
2014-07-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,660,235 |
|
- |
|
| Montreux Equity Partners V, L.p. |
10% Owner |
– – • |
2014-07-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,239,223 |
|
- |
|
| Diekman John D |
10% Owner |
– – • |
2014-07-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,214,910 |
|
- |
|
| Wyand Michael |
See Remarks |
• – – |
2014-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,641 |
21,641 |
|
- |
|
| Corrigan Mark |
Director |
– • – |
2014-07-15 |
4 |
D |
$11.80 |
$172,245 |
D/D |
(14,597) |
21,859 |
|
- |
|
| Munshi Amit |
Chief Executive Officer |
• • – |
2014-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
69,253 |
69,253 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2014-07-15 |
4 |
A |
$0.00 |
$0 |
I/I |
22,239,223 |
22,239,223 |
|
- |
|
36 Records found
|
|
Page 2 of 2 |
|
|
